Evidence map›Paper›PMID 40207727›Full record

ArticleHaematologica2025

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry.

Bente Houtman, Adele Taylor, Corine Van Marrewijk, Alexandra Smith, Pierre Fenaux, Catherine Cargo, Argiris Symeonidis, Moshe Mittelman, Reinhard Stauder, Jaroslav Čermák and 12 more

Abstract read
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Recurrent InvasiveCase reports in nephrology · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Bente HoutmanDep. of Hematology, Radboud University Medical Center, Nijmegen.
Adele TaylorEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York.
Corine Van MarrewijkDep. of Hematology, Radboud University Medical Center, Nijmegen.
Alexandra SmithEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York.
Pierre FenauxService d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris.
Catherine CargoHaematological Malignancy Diagnostic Service, Leeds Cancer Centre, St James's University Hospital and Leeds Teaching Hospitals NHS Trust, Leeds.
Argiris SymeonidisDep. of Medicine, Div. Hematology, University of Patras Medical School and Olympion General clinic, Patras.
Moshe MittelmanDep. of Hematology, Aviv Sourasky (Ichilov) Medical Center and Medical Faculty, Aviv University, Aviv 6423906.
Reinhard StauderDep. of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck.
Jaroslav ČermákDep. of Clinical Hematology, Inst. of Hematology and Blood Transfusion, Praha, Czech Republic.
Guillermo SanzInstituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe and CIBERONC,Valencia.
Eva Hellström-LindbergDep. of Medicine, Karolinska Institutet and Department of Hematology, Karolinska University Hospital, Stockholm.
Luca MalcovatiDep of Molecular Medicine, University of Pavia, Pavia, Italy; Dep. of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia.
Lionel AdèsService d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris.
Thibault ComontDep. of Internal Medicine - IUCT Oncopole - Toulouse University Hospital, Toulouse.
Dominic CulliganDep. of Haematology, Aberdeen Royal Infirmary, Aberdeen.
Ioannis KotsianidisDep. of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis.
Theo De WitteDep. of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen.
Nicole BlijlevensDep. of Hematology, Radboud University Medical Center, Nijmegen.
Saskia LangemeijerDep. of Hematology, Radboud University Medical Center, Nijmegen.
Marlijn HoeksDep. of Hematology, Radboud University Medical Center, Nijmegen. marlijn.hoeks@radboudumc.nl.
Eumds Consortium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes (LR-MDS). Studies regarding risk factors for infections are, however, limited in this population. This study aimed to investigate the prevalence and risk factors for infections and infection-related death in patients with LR-MDS. The study included 2,552 patients from the European MDS (EUMDS) Registry, which prospectively collects observational data on newly diagnosed MDS patients from 17 countries. The prevalence of infections and infection-related death was determined. Risk factors for infections and infection-related death occurring within 1 year from diagnosis were analyzed in separate multivariable logistic regression models. A third model that only included LR-MDS patients who experienced an infectious episode within the first year after diagnosis was used to analyze risk factors associated with infection-related death in patients with an infectious episode. The prevalence of infections was 7.6%, and 24.6% of all deaths were due to infections. In multivariable analysis, an independent association with increased risk for infections was found for hemoglobin level <8 g/dL, platelet count <50x109/L, absolute neutrophil count <0.8x109/L, intermediate/poor/very poor cytogenetics, and having received red blood cell transfusions at baseline. An independent association with increased risk of infection-related death was found for older age at diagnosis, hemoglobin level <8 g/dL, and platelet count <50x109/L. Patients with an increased risk of infections could benefit from close monitoring, especially in the first months after diagnosis. Future research should focus on the causality and severity of infections and risk factors over time, to provide more guidance for monitoring.

Indexed as

InfectionsMyelodysplastic SyndromesAdultAgedAged, 80 and overEuropeFemaleHumansMaleMiddle AgedPrevalenceRegistriesRisk Factors

Identifiers

PMID40207727
PMCPMC12485349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.